ライフサイエンスコーパス: core binding factor

1 inding sites for ETS-domain proteins and the core binding factor.

2 not affect the expression of osteocalcin and core binding factor.

3 s a DNA-binding subunit of the heterodimeric core-binding factor.

4 teins that either can or cannot activate the core binding factor 1 (CBF1) in 32D (clone 3) myeloblast

5 ptor gamma (PPARgamma), leptin, osteonectin, core binding factor 1 (CBFA1), and FBJ murine osteosarco

6 s studied include transcription factors like core binding factor 1 (Cbfa1), bone morphogenetic protei

7 Core-binding factor 1 (Cbfa1; also called Runx2) is a tr

8 on of the osteogenic markers osteocalcin and core-binding factor-1 genes, the latter of which is cons

9 We identified core-binding factor a1 binding to the runt domain bindin

10 on of both c-Fos and c-Jun in osteoblasts or core-binding factor a1 increased collagenase-3 promoter

11 hermore, overexpression of c-Fos, c-Jun, and core-binding factor a1 synergistically increased collage

12 ulted in the inability of c-Fos and c-Jun or core-binding factor a1 to increase collagenase-3 promote

13 Overexpression of Fra-2 and JunD repressed core-binding factor a1-induced collagenase-3 promoter ac

14 ed from patient platelet RNA exons 3 to 6 of core-binding factor A2 (CBFA2) cDNA, which encompasses t

15 -HSC function is highly reliant on continued core binding factor activity.

16 son between patients with FLT3-ITD, CBF-AML (Core binding factor acute myelogenous leukemia), and MLL

17 Not all patients with core binding factor acute myeloid leukemia (CBF-AML) dis

18 Timed-Sequential Induction in Patients With Core Binding Factor Acute Myeloid Leukemia and Treating

19 r measurable residual disease can persist in core-binding factor acute myeloid leukemia in otherwise

20 To identify cooperating lesions in core-binding factor acute myeloid leukemia, we performed

21 tance should provide important insights into core-binding factor acute myeloid leukemia.

22 Although core-binding factor-acute myeloid leukemia (CBF-AML) (t[

23 c mutations that cause G4 MB converge on the core binding factor alpha (CBFA) complex and mutually ex

24 Core binding factor alpha (Cbfa) mRNA, expressed constit

25 RUNX1 (AML1) encodes the core binding factor alpha subunit of a heterodimeric tra

26 ion of the osteoblast differentiation factor core binding factor alpha-1 (Cbfa1) and several bone-ass

27 including Id1, Id2, and Id3, associate with core binding factor alpha-1 (Cbfa1) to cause diminished

28 Core binding factor alpha-1 (Cbfa1), a member of the run

29 lysis for gene expression (up to 10 days for core binding factor alpha-1 [Cbfa1], bone sialoprotein [

30 ne expression using Northern blot for Cbfal (core binding factor alpha-1); OCN (osteocalcin), OPN (os

31 Gene expression of core binding factor alpha-1, an osteoblast-specific tran

32 olyoma enhancer-binding protein (PEBP2alpha)/core-binding factor alpha (CBFA) class are key transacti

33 gene AML1, encoding the transcription factor core-binding factor alpha (CBFalpha).

34 tein (MEPE); bone markers: osteocalcin (OC), core-binding factor alpha 1 (CBFalpha1), and alkaline ph

35 Transcription factors of the AML (core binding factor-alpha/polyoma enhancer binding prote

36 Our results of the expression pattern of core binding factor alpha1 (Cbfa1), which binds to the r

37 inding activity of the transcription factor, core binding factor alpha1 (Cbfa1).

38 gerprint, marked by the transcription factor core binding factor alpha1.

39 proteins including the transcription factor core-binding factor alpha1 (Cbfa1).

40 the osteoblast-specific transcription factor core-binding factor alpha1 (Cbfa1).

41 ns containing polyglutamine tracts including core-binding factor alpha1, mediator subunit 12, transcr

42 imulated cells expressed increased levels of core-binding factor alpha1, osteocalcin, alkaline phosph

43 the osteoblast-specific transcription factor core-binding factor alpha1/Runx2.

44 We report that the Ets-1 partner protein core-binding factor alpha2 (CBFalpha2; also known as AML

45 Core-binding factor alpha2 (CBFalpha2; otherwise known a

46 hin AML and are usually reported together as core binding factor AML (CBF-AML).

47 16 to 60 years of age, excluding those with core binding factor AML and acute promyelocytic leukemia

48 Patients with core binding factor AML treated with DA and one dose of

49 Among all patients without core binding factor AML who received standard induction

50 By contrast, in patients with core binding factor AML, outcomes were excellent with DA

51 In non-core binding factor AML, subclone formation was associat

52 For some AML categories, namely core-binding factor AML and/or cytogenetically normal AM

53 We suggest that patients with core-binding factor AML should be screened for mutKIT at

54 avourable-risk cytogenetics (eg, t[15;17] or core-binding factor AML) or who had received previous BC

55 Although both heterodimeric subunits of core binding factors (AML1/RUNX1 and CBFbeta) essential

56 The core binding factors are a small family of transcription

57 Core binding factors are heterodimeric transcription fac

58 nx family members can interact with Cbfbeta (core-binding factor b, encoded by Cbfb), a role for Cbfb

59 f complex is composed of the unique cofactor core binding factor beta (CBF-beta) and canonical ligase

60 A related protein, known as core binding factor beta (CBFbeta) also binds to the RD

61 ene encodes a chimeric protein involving the core binding factor beta (CBFbeta) and the smooth-muscle

62 e Runt-related transcription factor 1 (RUNX)/core binding factor beta (CBFbeta) complexes.

63 ants and analyze the possible involvement of core binding factor beta (CBFbeta) in this process.

64 e report that the transcriptional controller core binding factor beta (CBFbeta) is required for ILC2

65 sion between the transcription factor called core binding factor beta (CBFbeta) on 16q and a smooth m

66 DNA binding and heterodimerization with the core binding factor beta (CBFbeta) subunit.

67 The AML1/core binding factor beta (CBFbeta) transcription factor

68 Vif variants to the transcriptional cofactor core binding factor beta (CBFbeta), which is expressed i

69 We have expressed several variants of core binding factor beta (CBFbeta)-smooth muscle myosin

70 ty of Vif critically depends on the cellular core binding factor beta (CBFbeta).

71 e transcription factor fusion CBFbeta-SMMHC (core binding factor beta and the smooth-muscle myosin he

72 ng of most of the runt-related X1 co-factor, core binding factor beta fused to the smooth muscle myos

73 duct that fuses the first 165 amino acids of core binding factor beta to the coiled-coil region of a

74 in acts by dominantly interfering with AML-1/core binding factor beta-dependent transcriptional regul

75 K4b expression was caused by inv(16)-encoded core binding factor beta-smooth muscle myosin heavy chai

76 Core-binding factor beta (CBFbeta) and CBFalpha2 form a

77 lex with HIV-1 Vif and the cellular cofactor core-binding factor beta (CBFbeta) at 3.9- angstrom reso

78 The gene encoding for core-binding factor beta (CBFbeta) is altered in acute m

79 Core-binding factor beta (Cbfbeta) is the common non-DNA

80 Core-binding factor beta (CBFbeta) is the non-DNA-bindin

81 dimerization with another subunit called the core-binding factor beta (CBFbeta) subunit.

82 strong expression of RUNX1 and its cofactor, core-binding factor beta (CBFbeta), in megakaryocytes an

83 he presence of AML-1 and its partner protein core-binding factor beta in this osteoblast-restricted c

84 he RUNX1 Runt-Homology-Domain (RHD) with the core-binding factor beta protein (CBFbeta).

85 ts interaction with the transcription factor core-binding factor beta subunit (CBFbeta), and induces

86 eins and correlated with the binding of Runx/core-binding factor beta to regulatory elements within t

87 nd interacts with the AML-1-binding protein, core-binding factor beta.

88 ription factor 1 (RUNX1) and its associating core binding factor-beta (CBFB) play pivotal roles in le

89 The Runx1/core binding factor-beta (CBFbeta) transcriptional compl

90 os, c-Jun, osteoblast-specific factor-2, and core binding factor-beta increased the response to parat

91 tes transcription in part by helping recruit core binding factors, but nothing is known about the mec

92 minimal residual disease (MRD) monitoring in core binding factor (CBF) acute myeloid leukemia (AML) b

93 icated as a prognostic factor in adults with core binding factor (CBF) acute myeloid leukemia (AML).

94 ding the AML1 (RUNX1) or CBFbeta subunits of core binding factor (CBF) are commonly altered by transl

95 The inv(16) fuses the core binding factor (CBF) beta subunit with the coiled-c

96 eins, we found that the human enhancer bound core binding factor (CBF) between the muA and mu element

97 were, in 5'-to-3' order, a binding site for core binding factor (CBF) called core II, a binding site

98 AML1/RUNX1, a member of the core binding factor (CBF) family stimulates myelopoiesis

99 ing subunit of a transcription factor of the core binding factor (CBF) family, is required for the es

100 Because both t(8;21) and inv(16) disrupt core binding factor (CBF) in acute myeloid leukemia (AML

101 Core Binding Factor (CBF) is required for the developmen

102 Core binding factor (CBF) leukemias, those with transloc

103 Core binding factor (CBF) participates in specification

104 Runt domain is the DNA binding domain of the core binding factor (CBF) Runx subunits.

105 a luciferase gene, focusing initially on the core binding factor (CBF) site, which is footprinted in

106 Mutation of a core binding factor (CBF)-binding site at -288 decreased

107 binding protein CBFbeta as a complex termed core binding factor (CBF).

108 In the core binding factor (CBF)beta-smooth muscle myosin heavy

109 a binding site for the transcription factor core binding factor (CBF; also called AML1, PEBP2, and S

110 val, complex > or = 5, rare aberrations, and core-binding factor (CBF) abnormalities were prognostic

111 Core-binding factor (CBF) acute myeloid leukemia (AML) i

112 However, core-binding factor (CBF) AML treated with FLAG/DNX resu

113 served for t(15;17), MLL rearrangements, and core-binding factor (CBF) AMLs including both t(8;21) an

114 Core-binding factor (CBF) fusions RUNX1-ETO and CBFB-MYH

115 The core-binding factor (CBF) is a master regulator of devel

116 s with leukemogenic fusion proteins, such as core-binding factor (CBF) leukemia and MLL fusion leukem

117 t report of recurring FLT3 N676 mutations in core-binding factor (CBF) leukemias and suggests a defin

118 the DNA-binding subunit of the heterodimeric core-binding factor (CBF) that binds to the transcriptio

119 ties, including rearrangements involving the core-binding factor (CBF) transcriptional complex.

120 This fusion protein inhibits the core-binding factor (CBF), resulting in a block of hemat

121 The core-binding factor (CBF)-associated leukemia fusion pro

122 non-DNA-binding subunit of the heterodimeric core-binding factor (CBF).

123 betaRE and contains the transcription factor core-binding factor (CBF; also known as acute myeloid le

124 Core-binding factors (CBF) are heteromeric transcription

125 protein that binds the core site, one of the core-binding factors (CBF) is highly expressed in thymus

126 tectable in 165/1026 (16.1%) of aberrant non-core-binding-factor (CBF) karyotype patients.

127 RUNX1/CBFbeta (core binding factor [CBF]) is a heterodimeric transcript

128 The beta-subunit of core binding factor (CBFbeta), that heterodimerizes with

129 Core Binding Factors (CBFs) are a small group of heterod

130 BFbeta is the non-DNA binding subunit of the core binding factors (CBFs).

131 Core-binding factors (CBFs) are a small family of hetero

132 Core-binding factors (CBFs) are a small family of hetero

133 Core-binding factors (CBFs) are a small family of hetero

134 B) is a DNA-binding subunit in the family of core-binding factors (CBFs), heterodimeric transcription

135 transcription factor in the small family of core-binding factors (CBFs).

136 mily of heterodimeric transcription factors, core-binding factors (CBFs).

137 DNA binding components of the heterodimeric core binding factor complex.

138 The core binding factor composed of CBFB and RUNX subunits p

139 velopment, and situate an essential role for core-binding factors during the earliest stages of T-cel

140 that members of the activator protein-1 and core-binding factor families, binding to the activator p

141 es of hematopoiesis for which members of the core binding factor family are required, as well as the

142 bind members of the activator protein-1 and core-binding factor family of transcription factors, res

143 %): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormaliti

144 We examined the collective role of core-binding factors in hematopoiesis with a hypomorphic

145 The family of core-binding factors includes the DNA-binding subunits R

146 The Core Binding Factor is a heterodimeric transcription fac

147 Runx1 (AML1), the DNA binding subunit of a core binding factor, is required for the emergence and/o

148 Patients with core binding factor leukemia achieving complete remissio

149 The core binding factor leukemias with the translocations t(

150 Fbeta interaction as a therapeutic target in core binding factor leukemias.

151 of KIT occur in almost half of patients with core-binding factor leukemias, in which they have been a

152 acute myeloid leukemia 1, also called RUNX1, core binding factor protein (CBF alpha), and PEBP2 alpha

153 utations, KIT mutations, FLT3 mutations, and core binding factor rearrangements in AML, and JAK2 muta

154 on of nuclear factor, erythroid 2 (Nfe2) and core-binding factor, runt domain, alpha subunit 2, trans

155 aemogenic endothelium population whereas the core binding factor Runx1 (also known as AML1) is critic

156 nv(16)/t(16;16) rearrangements affecting the core-binding factors RUNX1 and CBFB, respectively, are f

157 ndependence in EMPs is not mediated by other core binding factors (Runx2 and/or Runx3); however, dele

158 ns of vascular endothelial growth factor and core-binding factor subunit alpha-1 were equivalent to c

159 ns of vascular endothelial growth factor and core-binding factor subunit alpha-1 were equivalent to c

160 ne morphogenetic proteins (BMP-2 and BMP-4), core-binding factor subunit alpha-1/Runt-related transcr

161 Because core-binding factor subunit beta and CypA are both highl

162 ch as HIV-1 utilize the transcription factor core-binding factor subunit beta as a noncanonical cofac

163 host cell proteins Elongin-C, Elongin-B, and core-binding factor subunit beta, forming a four-protein

164 significantly higher in AML-associated with core binding factor translocations or mutations in CEBPA

165 ized to one of three cytogenetic groups: (a) core binding factor type [(CBF); ie., t(8;21) inv(16), t